This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belayev, L. Articles by Ginsberg, M. D. Search for Related Content PubMed PubMed Citation Articles by Belayev, L. Articles by Ginsberg, M. D.

(Stroke. 1995;26:2313-2320.)
© 1995 American Heart Association, Inc.

Articles

HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat

Ludmila Belayev, MD; Raul Busto, BS; Weizhao Zhao, PhD Myron D. Ginsberg, MD

From the Cerebral Vascular Disease Research Center, Department of Neurology, University of Miami School of Medicine (Fla).

Background and Purpose HU-211 is a nonpsychotropic cannabinoid analogue that has been shown to act as a functional N-methyl-D-aspartate receptor blocker. We investigated the neuroprotective efficacy of HU-211 in a model of reversible middle cerebral artery occlusion (MCAo) in rats.

Methods Male Wistar rats were anesthetized with halothane and subjected to 90 minutes of temporary MCAo by retrograde insertion of an intraluminal nylon suture, coated with poly-L-lysine, through the external carotid artery into the internal carotid artery and MCA. The drug (HU-211 in cosolvent, 4 mg/kg IV) or vehicle was administered in a blinded fashion 70 minutes after onset of MCAo. Behavioral tests were evaluated during occlusion (60 minutes) and for a 3-day period after MCAo. Three days after MCAo, brains were perfusion-fixed, and infarct volumes were determined.

Results HU-211 significantly improved the neurological score compared with vehicle during the 3 days after MCAo. Treatment with HU-211 also significantly reduced both infarct volume (mean±SEM, 66.6±12.5 versus 149.8±36.3 mm³) and brain swelling (2.61±1.33% versus 6.66±1.24%) compared with vehicle-treated rats (n=17 in each group).

Conclusions These results demonstrate the neuroprotective ability of HU-211 in focal cerebral ischemia as judged by neurological score, infarct size, and brain swelling. Reversible MCAo with the use of a poly-L-lysine–coated intraluminal suture proved to be a reliable and effective modification of this technique, yielding consistent results.

Key Words: cerebral ischemia, focal • N-methyl-D-aspartate • neuroprotection • rats

This article has been cited by other articles:

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]

				A Guha Management of traumatic brain injury: some current evidence and applications Postgrad. Med. J., November 1, 2004; 80(949): 650 - 653. [Abstract] [Full Text] [PDF]

				V. Rema and F. F. Ebner Lesions of Mature Barrel Field Cortex Interfere with Sensory Processing and Plasticity in Connected Areas of the Contralateral Hemisphere J. Neurosci., November 12, 2003; 23(32): 10378 - 10387. [Abstract] [Full Text] [PDF]

				M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]

				F. C. Barone, E. A. Irving, A. M. Ray, J. C. Lee, S. Kassis, S. Kumar, A. M. Badger, R. F. White, M. J. McVey, J. J. Legos, et al. SB 239063, a Second-Generation p38 Mitogen-Activated Protein Kinase Inhibitor, Reduces Brain Injury and Neurological Deficits in Cerebral Focal Ischemia J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 312 - 321. [Abstract] [Full Text]

				E. F. Cregan, J. Peeling, D. Corbett, A. M. Buchan, J. Saunders, R. N. Auer, M. Gao, D. J. Mccarthy, M. S. Eisman, T. M. Campbell, et al. [(S)-Alpha-Phenyl-2-Pyridine-Ethanamine Dihydrochloride], A Low Affinity Uncompetitive N-Methyl-D-Aspartic Acid Antagonist, Is Effective in Rodent Models of Global and Focal Ischemia J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1412 - 1424. [Abstract] [Full Text]

				R. Gallily, A. Yamin, Y. Waksmann, H. Ovadia, J. Weidenfeld, A. Bar-Joseph, A. Biegon, R. Mechoulam, and E. Shohami Protection Against Septic Shock and Suppression of Tumor Necrosis Factor alpha  and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 918 - 924. [Abstract] [Full Text]

				D. C. Rogers, C. A. Campbell, J. L. Stretton, and K. B. Mackay Correlation Between Motor Impairment and Infarct Volume After Permanent and Transient Middle Cerebral Artery Occlusion in the Rat Stroke, October 1, 1997; 28(10): 2060 - 2066. [Abstract] [Full Text]

				L. Belayev, O. F. Alonso, R. Busto, W. Zhao, M. D. Ginsberg, and C. Y. Hsu Middle Cerebral Artery Occlusion in the Rat by Intraluminal Suture: Neurological and Pathological Evaluation of an Improved Model Stroke, September 1, 1996; 27(9): 1616 - 1623. [Abstract] [Full Text]

				A. I. Faden Pharmacologic Treatment of Acute Traumatic Brain Injury JAMA, August 21, 1996; 276(7): 569 - 570. [Abstract] [PDF]